
A study evaluated the impact of in-hospital initiation of sacubitril/valsartan (Sac/Val) therapy following acute heart failure (AHF). The study involved 400 patients and found that Sac/Val led to a greater reduction in NT-proBNP levels compared to continuing angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. At 4 and 8 weeks, NT-proBNP levels decreased by 35% and 45% in the Sac/Val group, compared to 18% and 32% in the control group. The treatment effect was more pronounced in patients with left ventricular ejection fraction < 40% and those in sinus rhythm. No adverse safety signals were observed, supporting Sac/Val's efficacy and safety.
Like
Save
Share